Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 09-2025 | 09-2024 | 09-2023 | 09-2022 | 09-2021 | |
| Sales | 65,324 | 67,635 | 79,204 | 86,160 | 97,074 |
| Gross Profit | 65,324 | 67,635 | 79,204 | 86,160 | 97,074 |
| Operating Expenses | 150,673 | 189,326 | 216,411 | 210,004 | 206,647 |
| Operating Income | -85,349 | -121,691 | -137,207 | -123,844 | -109,573 |
| Interest Expense | 7,681 | 10,940 | 5,148 | 0 | 0 |
| Other Income | 9,481 | 14,843 | 11,360 | 1,656 | 1,994 |
| Pre-tax Income | -83,549 | -117,788 | -130,995 | -122,188 | -107,579 |
| Income Tax | -1,660 | -1,743 | 2,821 | -433 | -28,583 |
| Net Income Continuous | -81,889 | -116,045 | -133,816 | -121,755 | -78,996 |
| Net Income | $-81,889 | $-116,045 | $-133,816 | $-121,755 | $-78,996 |
| EPS Basic Total Ops | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| EPS Basic Continuous Ops | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| EPS Diluted Total Ops | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| EPS Diluted Continuous Ops | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| EPS Diluted Before Non-Recurring Items | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| EBITDA(a) | $-80,260 | $-120,493 | $-137,692 | $-119,700 | $-104,123 |